Every state Medicaid program in the country, along with the District of Columbia and Puerto Rico, applied to a federal initiative built to bring most-favored-nation drug pricing to Medicaid. But as of September 18, only 40 of those states plus Puerto Rico had actually signed the agreements that make participation binding, and the Centers for Medicare & Medicaid Services says the remaining jurisdictions have until September 30 to close that gap. The distance between applying and signing is where the real story of the GENEROUS Model sits this month, not the fact that every Medicaid program in the country wanted in.
Applying and Signing Are Two Different Steps
The GENErating cost Reductions fOr U.S. Medicaid, or GENEROUS, Model asks participating drug manufacturers to make covered outpatient drugs available to state Medicaid programs at most-favored-nation pricing, meaning prices aligned with what other developed countries pay. Manufacturers invoice states directly for supplemental rebates that bring their prices down to that international benchmark, CMS monitors the accuracy of that pricing, and the federal government then reduces its own share of Medicaid reimbursement to capture part of the resulting savings. A state’s signature commits it to administering that rebate mechanism; applying only signaled interest in doing so.
That September 30 cutoff is itself a revised date, not the model’s original design. CMS extended the deadline for states to finalize participation agreements from an earlier August 31 target, part of a broader round of extensions announced in April that also moved the states’ application deadline from July 31 to September 10, the manufacturers’ application deadline from April 30 to June 11, and the manufacturers’ agreement deadline from June 30 to July 17.
Free download: Every document a Medicaid renewal may require, a deadline and proof tracker, and what to do after a termination notice. Get the free Medicaid renewal checklist.
The Manufacturer Side Sets the Real Discount
Signing on as a state is necessary but not sufficient to produce a lower price at any given pharmacy. Only drug manufacturers that participate in the Medicaid Drug Rebate Program and manufacture at least one covered outpatient drug are eligible to apply to the model, and it is a manufacturer’s separate agreement, not a state’s, that determines which specific drugs actually carry most-favored-nation pricing under a signed state’s Medicaid program.
The gap matters because CMS’s September count answers only the state half of the question. The agency’s release states that all 50 states, the District of Columbia and Puerto Rico applied, but it does not publish, as of that release, a matching count of which manufacturers have signed or which specific drugs are covered under agreements already in place, leaving the size of any beneficiary-level discount undetermined even in states that have already signed.
The Ten-Year Savings Number in Context
CMS frames the $64.3 billion in projected ten-year federal savings against a Medicaid drug budget that has grown sharply: gross Medicaid spending on prescription drugs exceeded $100 billion in 2024, up roughly $10 billion from 2022, and net spending, after manufacturer rebates are subtracted, still totaled about $60 billion that year. Measured against that base, $64.3 billion spread across a decade is closer to one additional year’s worth of net drug spending than a dramatic reduction in the program’s overall drug bill.
The savings reach the federal budget before they reach any individual Medicaid enrollee. Once a manufacturer’s supplemental rebate brings a drug’s price down to the international benchmark, CMS reduces its own share of Medicaid reimbursement to the state, capturing part of the savings as a lower federal payment obligation rather than as a rebate check or a price cut a beneficiary would notice directly at the pharmacy counter.
The model launched in January 2026 and is set to run for five years, a longer runway than many CMS Innovation Center pilots receive before the agency decides whether to expand, modify or end them. Five years of state and manufacturer participation, layered onto a signing process that is still incomplete seven months after launch, is what CMS is asking the $64.3 billion estimate to be judged against.
The Compliance Question CMS Hasn’t Answered
Nothing in CMS’s September 18 release states what happens to a state that misses the September 30 deadline for finalizing its agreement, the same deadline the agency already extended once. There is no published rule describing whether a state that misses the date is barred from the model until a future enrollment window, permitted to sign later without penalty, or excluded for the life of the five-year model, and CMS’s press materials do not address the question.
What CMS has published, and what stands as the verifiable record this month, is a three-part count: every eligible jurisdiction applied, 40 states plus Puerto Rico have signed, and the ten remaining states and the District of Columbia have until September 30, ten days after this article’s publication date, to close a gap in a deadline CMS has already moved once. Whether that count reaches all 52 jurisdictions by month’s end, and how many manufacturers ultimately sign alongside them, are the two facts that will determine whether the $64.3 billion estimate becomes a real number or stays a projection built on partial participation.
State Medicaid Decisions Reach Individual Enrollees
None of the state-by-state signing count above tells an individual Medicaid enrollee whether their own state’s renewal paperwork, reporting deadlines or eligibility redetermination will change because of the new drug-pricing agreement. Those renewal mechanics run on a separate, state-specific calendar that does not pause or adjust for a manufacturer or drug-pricing deal, and a missed renewal deadline can end coverage regardless of what a state has signed with CMS.
The SNAP & Medicaid Renewal Organizer is a 13-page organizer built around 51 state packs, a renewal document checklist and a renewal and reporting calendar to track deadlines separately from federal-level policy changes.
See the state renewal calendars and document checklist in The SNAP & Medicaid Renewal Organizer.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
